Alexander M. Castellino, PhD

Alexander Castellino is a freelance writer who has been writing in the oncology space for over 15 years. After graduating in the biological sciences, he decided that, for him, the pen was mightier than the bench. He started writing with Nature Biotechnology, contributing to their News in Brief. Alex writes across a wide variety of topics, and in oncology he works with the ASCO Daily News, Medscape Oncology, and Cancer Therapy Advisor. When he is not writing, Alex loves to read, cook, and travel.

Most Recent Articles by Alexander M. Castellino, PhD

Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma

Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma

By

A review published in Blood highlights new approaches that are being investigated to treat PCNSL based on the mutational landscape and signaling pathways that are extant in the disease.

Janus Kinase Inhibitors for the Treatment of Myelofibrosis

Janus Kinase Inhibitors for the Treatment of Myelofibrosis

By

The identification of driver mutations in myelofibrosis has helped cement understanding of the pathophysiology of the disease and has kick-started the development of targeted therapies.

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

By

Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

By

Similar ORR was reported for patients regardless of prior exposure to brentuximab vedotin (BV).

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

By

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

More Articles by Alexander M. Castellino, PhD

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs